PharmaCyte Total Assets vs Other Liab Analysis
| PMCB Stock | USD 2.10 0.01 0.48% |
PharmaCyte Biotech financial indicator trend analysis is much more than just breaking down PharmaCyte Biotech prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether PharmaCyte Biotech is a good investment. Please check the relationship between PharmaCyte Biotech Total Assets and its Other Liab accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PharmaCyte Biotech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade PharmaCyte Stock refer to our How to Trade PharmaCyte Stock guide.
Total Assets vs Other Liab
Total Assets vs Other Liab Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of PharmaCyte Biotech Total Assets account and Other Liab. At this time, the significance of the direction appears to have strong relationship.
The correlation between PharmaCyte Biotech's Total Assets and Other Liab is 0.64. Overlapping area represents the amount of variation of Total Assets that can explain the historical movement of Other Liab in the same time period over historical financial statements of PharmaCyte Biotech, assuming nothing else is changed. The correlation between historical values of PharmaCyte Biotech's Total Assets and Other Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Assets of PharmaCyte Biotech are associated (or correlated) with its Other Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Liab has no effect on the direction of Total Assets i.e., PharmaCyte Biotech's Total Assets and Other Liab go up and down completely randomly.
Correlation Coefficient | 0.64 |
| Relationship Direction | Positive |
| Relationship Strength | Significant |
Total Assets
Total assets refers to the total amount of PharmaCyte Biotech assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in PharmaCyte Biotech books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Other Liab
Most indicators from PharmaCyte Biotech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into PharmaCyte Biotech current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PharmaCyte Biotech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade PharmaCyte Stock refer to our How to Trade PharmaCyte Stock guide.At present, PharmaCyte Biotech's Sales General And Administrative To Revenue is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value Over EBITDA is expected to grow to 2.44, whereas Selling General Administrative is forecasted to decline to about 4.7 M.
PharmaCyte Biotech fundamental ratios Correlations
Click cells to compare fundamentals
PharmaCyte Biotech Account Relationship Matchups
High Positive Relationship
High Negative Relationship
PharmaCyte Biotech fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Other Current Liab | 816.6K | 552.5K | 499.0K | 458.3K | 527.0K | 467.7K | |
| Total Current Liabilities | 1.0M | 724.8K | 704.4K | 586.6K | 674.6K | 1.2M | |
| Total Stockholder Equity | 5.1M | 6.7M | 89.9M | 72.7M | 83.6M | 87.8M | |
| Retained Earnings | (103.9M) | (107.4M) | (111.6M) | (116.0M) | (104.4M) | (99.1M) | |
| Common Stock Total Equity | 101.3K | 118.6K | 163.9K | 159.0 | 182.85 | 173.71 | |
| Common Stock Shares Outstanding | 1.4B | 1.7B | 15.5M | 19.5M | 22.4M | 21.3M | |
| Other Stockholder Equity | 108.8M | (20.4K) | 201.6M | 188.7M | 217.0M | 227.8M | |
| Total Liab | 1.1M | 724.8K | 704.4K | 586.6K | 674.6K | 640.8K | |
| Common Stock | 163.9K | 159.0 | 2.1K | 2.2K | 2.5K | 2.4K | |
| Total Assets | 6.2M | 7.4M | 90.6M | 73.3M | 84.3M | 88.5M | |
| Net Debt | (819.7K) | (2.2M) | (85.4M) | (68.0M) | (61.2M) | (58.2M) | |
| Accounts Payable | 185.8K | 172.3K | 205.4K | 128.3K | 147.5K | 140.1K | |
| Cash | 894.9K | 2.2M | 85.4M | 68.0M | 78.2M | 82.2M | |
| Cash And Short Term Investments | 2.5M | 2.2M | 85.4M | 68.0M | 78.2M | 82.2M | |
| Liabilities And Stockholders Equity | 6.2M | 7.4M | 90.6M | 73.3M | 84.3M | 88.5M | |
| Total Current Assets | 1.0M | 2.3M | 85.5M | 68.1M | 78.4M | 82.3M | |
| Other Current Assets | (1.4M) | 73.1K | 94.2K | 107.7K | 96.9K | 92.1K | |
| Accumulated Other Comprehensive Income | (21.7K) | (20.4K) | (15.8K) | (23.0K) | (26.5K) | (27.8K) | |
| Net Tangible Assets | 1.5M | 1.5M | 3.1M | 86.4M | 99.3M | 104.3M | |
| Net Invested Capital | 5.2M | 6.7M | 89.9M | 72.7M | 83.6M | 87.8M | |
| Net Working Capital | 6.2K | 1.6M | 84.8M | 67.6M | 77.7M | 81.6M | |
| Capital Stock | 163.9K | 159.0 | 2.1K | 2.2K | 1.9K | 1.8K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether PharmaCyte Biotech offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of PharmaCyte Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Pharmacyte Biotech Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Pharmacyte Biotech Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PharmaCyte Biotech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade PharmaCyte Stock refer to our How to Trade PharmaCyte Stock guide.Note that the PharmaCyte Biotech information on this page should be used as a complementary analysis to other PharmaCyte Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Complementary Tools for PharmaCyte Stock analysis
When running PharmaCyte Biotech's price analysis, check to measure PharmaCyte Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PharmaCyte Biotech is operating at the current time. Most of PharmaCyte Biotech's value examination focuses on studying past and present price action to predict the probability of PharmaCyte Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PharmaCyte Biotech's price. Additionally, you may evaluate how the addition of PharmaCyte Biotech to your portfolios can decrease your overall portfolio volatility.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |
Is PharmaCyte Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PharmaCyte Biotech. If investors know PharmaCyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PharmaCyte Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.48) | Return On Assets (0.05) | Return On Equity (0.02) |
The market value of PharmaCyte Biotech is measured differently than its book value, which is the value of PharmaCyte that is recorded on the company's balance sheet. Investors also form their own opinion of PharmaCyte Biotech's value that differs from its market value or its book value, called intrinsic value, which is PharmaCyte Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PharmaCyte Biotech's market value can be influenced by many factors that don't directly affect PharmaCyte Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PharmaCyte Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if PharmaCyte Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PharmaCyte Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.